In this study, we report on achievable treatment plan dose volume histogram (DVH) metrics, prostate-specific antigen (PSA) response, and physician-reported toxicities for prostate cancer patients treated with SBRT using real-time adaptive motion management. This evidence concerns the gene KLK3 and Familial prostate cancer.